Brokerages Set Pulmonx Corporation (NASDAQ:LUNG) PT at $5.58

Shares of Pulmonx Corporation (NASDAQ:LUNG) have received an average rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $5.5833.

Several equities analysts have weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a research report on Thursday, April 30th. Wall Street Zen downgraded Pulmonx from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Canaccord Genuity Group dropped their target price on Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, March 5th.

Pulmonx Stock Up 1.3%

Shares of NASDAQ:LUNG opened at $1.61 on Wednesday. The company has a market capitalization of $68.01 million, a price-to-earnings ratio of -1.24 and a beta of 0.28. The company has a current ratio of 4.91, a quick ratio of 4.04 and a debt-to-equity ratio of 0.81. The business has a 50-day moving average price of $1.36 and a 200 day moving average price of $1.67. Pulmonx has a 12-month low of $1.13 and a 12-month high of $3.88.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share for the quarter, meeting the consensus estimate of ($0.33). The company had revenue of $20.59 million during the quarter, compared to the consensus estimate of $20.43 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. Sell-side analysts expect that Pulmonx will post -1.13 EPS for the current year.

Hedge Funds Weigh In On Pulmonx

Several institutional investors have recently bought and sold shares of LUNG. XTX Topco Ltd acquired a new position in Pulmonx in the 2nd quarter valued at about $149,000. Norges Bank acquired a new position in shares of Pulmonx during the second quarter worth about $392,000. Jane Street Group LLC grew its position in shares of Pulmonx by 3,328.7% during the second quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock worth $230,000 after buying an additional 86,046 shares in the last quarter. Bank of America Corp DE grew its position in shares of Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after buying an additional 407,971 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Pulmonx by 95.8% during the third quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock worth $40,000 after buying an additional 12,166 shares in the last quarter. 91.04% of the stock is owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.